2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P11625
    R9-13 98%
    R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure.
    R9-13
  • HY-P11630
    ZM-804 98%
    ZM-804 is a cationic α-helix antimicrobial peptide. ZM-804 targets bacterial cell membranes. ZM-804 demonstrates antimicrobial activity and prevents the infection of tomato plants by Pst DC3000. ZM-804 inhibits the growth of B. subtilis and E. coli (the same MICs of 41.10 μg/mL). ZM-804 exhibits low hemolytic activity.
    ZM-804
  • HY-P11650
    HE4-1 leech peptide 2531396-44-6
    HE4-1 leech peptide is a p38 MAPK inhibitor with an additional c-Jun N-terminal kinase (JNK) inhibitory role. HE4-1 leech peptide suppresses macrophage migration, and does not significantly affect macrophage immunological activities including phagocytic ability, lysozyme activity, and expression levels of most inflammatory factors. HE4-1 leech peptide can be used for the research of atherosclerosis.
    HE4-1 leech peptide
  • HY-P1166A
    UFP-803 TFA 98%
    UFP-803 TFA is a potent urotensin-II receptor (UT) ligand. UFP-803 TFA has lower residual agonist activity, so it may be an important tool for the investigations on the role played by the UT system in physiology and pathology.
    UFP-803 TFA
  • HY-P1167A
    [Orn5]-URP TFA 98%
    [Orn5]-URP TFA is a potent and selective pure antagonist of Urotensin-II receptor (UT), with an pEC50 of 7.24. [Orn5]-URP TFA displays no agonist activity.
    [Orn5]-URP TFA
  • HY-P11775
    Peptide HRH 1228536-06-8 98%
    Peptide HRH is a polypeptide that specifically binds to VEGF receptors. Peptide HRH inhibits VEGF-stimulated endothelial cell proliferation. Peptide HRH inhibits angiogenesis and suppresses corneal neovascularization. Peptide HRH can be used in anti-angiogenesis related studies.
    Peptide HRH
  • HY-P11777
    AG73 170655-66-0 98%
    AG73 is a polypeptide. AG73 is derived from the G domain of the Laminin α1 chain. AG73 binds heparin, Syndecan-1 and Syndecan-4. AG73 promotes the adhesion of various cells, induces the differentiation of salivary gland acinar cells, stimulates neurite outgrowth, secretion of matrix metalloproteinases and angiogenesis. AG73 retains its angiogenic activity when conjugated to chitosan membranes. AG73 can be used in the research of melanoma and ischemic injury.
    AG73
  • HY-P11798
    P-Selectin binding peptide
    P‑Selectin binding peptide is a short peptide that specifically targets P‑selectin. P‑Selectin binding peptide binds with high affinity to P‑selectin, which is highly expressed on activated platelets, inflamed endothelium, and in the tumor microenvironment. P‑Selectin binding peptide is used for precise targeted delivery and intervention in inflammation, thrombosis, and tumors.
    P-Selectin binding peptide
  • HY-P1184A
    HNGF6A TFA 98%
    HNGF6A TFA is a humanin analogue. HNGF6A TFA increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A TFA inhibits of ROS production during oxidative stress. HNGF6A TFA can prevent endothelial dysfunction and atherosclerosis in vivo.
    HNGF6A TFA
  • HY-P1214A
    γ1-MSH TFA 98%
    γ1-MSH TFA is a melanocortin MC3 receptor agonist, with a Ki of 34 nM for the rat MC3 receptor. γ1-MSH TFA displays ~40-fold selectivity over MC4 (Ki=1318 nM).
    γ1-MSH TFA
  • HY-P1262A
    Parstatin(human) TFA 98%
    Parstatin(human) TFA, a cell-penetrating PAR-1 thrombin receptor agonist peptide, is a potent inhibitor of angiogenesis.
    Parstatin(human) TFA
  • HY-P1306A
    Obestatin(rat) TFA 1312186-27-8 98%
    Obestatin(rat) TFA, encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) TFA suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain. Obestatin is an endogenous ligand of G-protein coupled receptor 39 (GPR39). Obestatin(rat) TFA has anti-inflammatory, anti-myocardial infarction and antioxidant activities.
    Obestatin(rat) TFA
  • HY-P1419A
    AP 811 acetate 98%
    AP 811 acetate is a selective atrial natriuretic peptide clearance receptor (ANP-CR, NPR3) antagonist with a Ki of 0.48 nM. AP 811 acetate displays >20000-fold selectivity for NPR3 over NPR1. AP 811 acetate abolishes ANP-induced pump stimulation.
    AP 811 acetate
  • HY-P1428A
    RFRP-1(human) TFA 98%
    RFRP-1(human) TFA is a potent endogenous NPFF receptor agonist (EC50 values are 0.0011 and 29 nM for NPFF2 and NPFF1, respectively). Attenuates contractile function of isolated rat and rabbit cardiac myocytes. Reduces heart rate, stroke volume, ejection fraction and cardiac output, and increases plasma prolactin levels in rats.
    RFRP-1(human) TFA
  • HY-P1435A
    NoxA1ds TFA 98%
    NoxA1ds TFA is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC50=20 nM). NoxA1ds TFA inhibits NOX1-derived O2- production in HT-29 human colon cancer cells. NoxA1ds TFA attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds TFA can be used in the study of hypertension, atherosclerosis and tumors.
    NoxA1ds TFA
  • HY-P1471A
    Adrenomedullin (AM) (22-52), human TFA 98%
    Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin human) TFA, an NH2 terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist. Adrenomedullin (AM) (22-52), human also antagonizes the calcitonin generelated peptide (CGRP) receptor in the hindlimb vascular bed of the cat.
    Adrenomedullin (AM) (22-52), human TFA
  • HY-P1486A
    Angiotensinogen (1-14), human TFA 98%
    Angiotensinogen (1-14), human TFA is a fragment of the renin substrate angiotensinogen. Angiotensinogen is naturally occurring substrate for renin and a precursor for all angiotensin peptides.
    Angiotensinogen (1-14), human TFA
  • HY-P1488A
    Bradykinin (1-5) TFA
    Bradykinin (1-5) (TFA) is a major stable metabolite of Bradykinin (HY-P0206), formed by the proteolytic action of angiotensin-converting enzyme (ACE). Bradykinin (1-5) (TFA) inhibits α- and γ-thrombin-induced platelet aggregation.
    Bradykinin (1-5) TFA
  • HY-P1548B
    β-CGRP, human acetate 98%
    β-CGRP, human acetate (Human β-CGRP acetate) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC50s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.
    β-CGRP, human acetate
  • HY-P1573A
    Brain Natriuretic Peptide-45, rat TFA 98%
    Brain Natriuretic Peptide-45, rat TFA (BNP-45, rat TFA) is a circulating form of rat brain natriuretic peptide isolated from rat heart with potent hypotensive and natriuretic potency.
    Brain Natriuretic Peptide-45, rat TFA
Cat. No. Product Name / Synonyms Application Reactivity